Fourier transform–ion cyclotron resonance (FT-ICR) is an advanced form of MS characterized by unrivaled mass accuracy and resolving power. In fact, the systems that use this technology tend to be quite large, and are mostly found in R&D labs where a requirement for extremely high performance can justify the high cost. In a typical MS, […]
Pharma R&D expenditures rise almost 10% in 2016
China dominates global chemical sales in 2016
Japanese scientific output continues to decline
Chemical companies’ R&D spending slightly increased in 2017
UK’s fate collaborating with EU countries on scientific research remains unclear
Companies deliver growth in fourth quarter results
Since the publication of the February 28 issue of IBO (see IBO 2/28/18), which included estimated figures for the IBO Life Science and Analytical Instrument Indexes (LSA Indexes), quarterly and annual estimates have been finalized for three companies: Bio-Rad Laboratories Life Science, Merck KGaA Life Science and NanoString Technologies. The updated financial results affect the IBO Life […]
Single-digit losses for both Indexes
In what is viewed as a step forward for NGS-based clinical testing, the US Centers for Medicare & Medicaid Services (CMS) announced this month a final National Coverage Determination (NCD) for FDA-approved NGS tests for advanced cancer (defined as either recurrent, relapsed, refractory, metastatic, or advanced stages III or IV) patients as long as certain […]
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
